http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 16 Jul 2026 18:18:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PFIZER+INC++++++++++++++++For%3A+Jul+15++Filed+by%3A+BOURLA+ALBERT/26780828.html si-local-file:///var/storage/secattach/20260716/26780828.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PFIZER+INC++++++++++++++++For%3A+Jul+15++Filed+by%3A+BOURLA+ALBERT/26780828.html Thu, 16 Jul 2026 18:18:00 -0400 O.00000313 PFE http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PFIZER+INC++++++++++++++++For%3A+Jul+15++Filed+by%3A+BOURLA+ALBERT/26780828.html si-local-file:///var/storage/secattach/20260716/26780828.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PFIZER+INC++++++++++++++++For%3A+Jul+15++Filed+by%3A+BOURLA+ALBERT/26780828.html Thu, 16 Jul 2026 18:18:00 -0400 O.00000313 PFE http://www.streetinsider.com/Trader+Talk/Pfizer+temporarily+discontinues+premarin+vaginal+cream+in+India%2C+citing+supply+challenges+-+Reuters/26778909.html (Updated - July 16, 2026 1:37 PM EDT) <p>Pfizer temporarily discontinues premarin vaginal cream in India, citing supply challenges - Reuters</p><ul><li>The decision was driven by "certain supply challenges," said Trupti Wagh, Pfizer's senior director of media relations for APAC.</li></ul> http://www.streetinsider.com/Trader+Talk/Pfizer+temporarily+discontinues+premarin+vaginal+cream+in+India%2C+citing+supply+challenges+-+Reuters/26778909.html Thu, 16 Jul 2026 13:37:27 -0400 PFE http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PFIZER+INC++++++++++++++++For%3A+Jul+09++Filed+by%3A+BOURLA+ALBERT/26762319.html si-local-file:///var/storage/secattach/20260713/26762319.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PFIZER+INC++++++++++++++++For%3A+Jul+09++Filed+by%3A+BOURLA+ALBERT/26762319.html Mon, 13 Jul 2026 15:43:00 -0400 O.00000313 PFE http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PFIZER+INC++++++++++++++++For%3A+Jul+09++Filed+by%3A+BOURLA+ALBERT/26762319.html si-local-file:///var/storage/secattach/20260713/26762319.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PFIZER+INC++++++++++++++++For%3A+Jul+09++Filed+by%3A+BOURLA+ALBERT/26762319.html Mon, 13 Jul 2026 15:43:00 -0400 O.00000313 PFE http://www.streetinsider.com/Analyst+PT+Change/Pfizer+%28PFE%29+PT+Lowered+to+%2430+at+BMO+Capital/26759861.html <p>BMO Capital analyst Evan David Seigerman lowered the price target on Pfizer (NYSE: PFE) to $30.00 (from $34.00) while maintaining a Outperform rating.</p> http://www.streetinsider.com/Analyst+PT+Change/Pfizer+%28PFE%29+PT+Lowered+to+%2430+at+BMO+Capital/26759861.html Mon, 13 Jul 2026 07:37:00 -0400 PFE http://www.streetinsider.com/Analyst+PT+Change/Pfizer+%28PFE%29+PT+Lowered+to+%2435+at+Guggenheim/26759483.html (Updated - July 13, 2026 6:53 AM EDT) <p>Guggenheim analyst Vamil Divan lowered the price target on Pfizer (NYSE: PFE) to $35.00 (from $36.00) while maintaining a Buy rating.</p><p>The analyst commented: "We are updating our Pfizer company model ahead of the company's 2Q 2026 earnings release on Aug 4. We have adjusted our quarterly estimates based on our latest review of IQVIA (IQV) prescription data and our recent check-in with the PFE investor relations team. Overall we are close to consensus for 2Q 2026 (Gugg at $14.1Bn for sales and $0.67 for EPS vs. FactSet Consensus at $14.4Bn for sales and http://www.streetinsider.com/Analyst+PT+Change/Pfizer+%28PFE%29+PT+Lowered+to+%2435+at+Guggenheim/26759483.html Mon, 13 Jul 2026 06:53:19 -0400 PFE http://www.streetinsider.com/Analyst+Comments/Pfizer+%28PFE%29+PT+Lowered+to+%2435+at+Guggenheim/26759483.html (Updated - July 13, 2026 6:53 AM EDT) <p>Guggenheim analyst Vamil Divan lowered the price target on Pfizer (NYSE: PFE) to $35.00 (from $36.00) while maintaining a Buy rating.</p><p>The analyst commented: "We are updating our Pfizer company model ahead of the company's 2Q 2026 earnings release on Aug 4. We have adjusted our quarterly estimates based on our latest review of IQVIA (IQV) prescription data and our recent check-in with the PFE investor relations team. Overall we are close to consensus for 2Q 2026 (Gugg at $14.1Bn for sales and $0.67 for EPS vs. FactSet Consensus at $14.4Bn for sales and http://www.streetinsider.com/Analyst+Comments/Pfizer+%28PFE%29+PT+Lowered+to+%2435+at+Guggenheim/26759483.html Mon, 13 Jul 2026 06:53:19 -0400 PFE http://www.streetinsider.com/FDA/FDA+approves+Padcev+plus+Keytruda+for+muscle-invasive+bladder+cancer/26756280.html <p>The U.S. Food and Drug Administration has approved Padcev (enfortumab vedotin-ejfv) combined with Keytruda (pembrolizumab) as neoadjuvant and adjuvant treatment for adult patients with muscle-invasive bladder cancer (MIBC), regardless of cisplatin eligibility, according to a statement from Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503).</p> <p>The expanded approval builds on a November 2025 FDA approval of the same combination for cisplatin-ineligible MIBC patients and is now supported by data from the Phase 3 EV-304 clinical trial, also known as KEYNOTE-B15. The trial compared neoadjuvant and adjuvant Padcev plus pembrolizumab against neoadjuvant gemcitabine and cisplatin chemotherapy in cisplatin-eligible patients.</p> <p>Key results http://www.streetinsider.com/FDA/FDA+approves+Padcev+plus+Keytruda+for+muscle-invasive+bladder+cancer/26756280.html Fri, 10 Jul 2026 11:23:17 -0400 4503 A.06822034 A.13871217 A.15882755 A.22847412 O.00000313 O.00162698 O.01115933 O.01918044 O.03960636 O.20026344 PFE http://www.streetinsider.com/FDA/FDA+approves+Padcev+plus+Keytruda+for+muscle-invasive+bladder+cancer/26756280.html <p>The U.S. Food and Drug Administration has approved Padcev (enfortumab vedotin-ejfv) combined with Keytruda (pembrolizumab) as neoadjuvant and adjuvant treatment for adult patients with muscle-invasive bladder cancer (MIBC), regardless of cisplatin eligibility, according to a statement from Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503).</p> <p>The expanded approval builds on a November 2025 FDA approval of the same combination for cisplatin-ineligible MIBC patients and is now supported by data from the Phase 3 EV-304 clinical trial, also known as KEYNOTE-B15. The trial compared neoadjuvant and adjuvant Padcev plus pembrolizumab against neoadjuvant gemcitabine and cisplatin chemotherapy in cisplatin-eligible patients.</p> <p>Key results http://www.streetinsider.com/FDA/FDA+approves+Padcev+plus+Keytruda+for+muscle-invasive+bladder+cancer/26756280.html Fri, 10 Jul 2026 11:23:17 -0400 4503 A.06822034 A.13871217 A.15882755 A.22847412 O.00000313 O.00162698 O.01115933 O.01918044 O.03960636 O.20026344 PFE http://www.streetinsider.com/FDA/FDA+approves+Padcev+plus+Keytruda+for+muscle-invasive+bladder+cancer/26756280.html <p>The U.S. Food and Drug Administration has approved Padcev (enfortumab vedotin-ejfv) combined with Keytruda (pembrolizumab) as neoadjuvant and adjuvant treatment for adult patients with muscle-invasive bladder cancer (MIBC), regardless of cisplatin eligibility, according to a statement from Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503).</p> <p>The expanded approval builds on a November 2025 FDA approval of the same combination for cisplatin-ineligible MIBC patients and is now supported by data from the Phase 3 EV-304 clinical trial, also known as KEYNOTE-B15. The trial compared neoadjuvant and adjuvant Padcev plus pembrolizumab against neoadjuvant gemcitabine and cisplatin chemotherapy in cisplatin-eligible patients.</p> <p>Key results http://www.streetinsider.com/FDA/FDA+approves+Padcev+plus+Keytruda+for+muscle-invasive+bladder+cancer/26756280.html Fri, 10 Jul 2026 11:23:17 -0400 4503 A.06822034 A.13871217 A.15882755 A.22847412 O.00000313 O.00162698 O.01115933 O.01918044 O.03960636 O.20026344 PFE http://www.streetinsider.com/FDA/FDA+approves+Padcev+plus+Keytruda+for+muscle-invasive+bladder+cancer/26756280.html <p>The U.S. Food and Drug Administration has approved Padcev (enfortumab vedotin-ejfv) combined with Keytruda (pembrolizumab) as neoadjuvant and adjuvant treatment for adult patients with muscle-invasive bladder cancer (MIBC), regardless of cisplatin eligibility, according to a statement from Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503).</p> <p>The expanded approval builds on a November 2025 FDA approval of the same combination for cisplatin-ineligible MIBC patients and is now supported by data from the Phase 3 EV-304 clinical trial, also known as KEYNOTE-B15. The trial compared neoadjuvant and adjuvant Padcev plus pembrolizumab against neoadjuvant gemcitabine and cisplatin chemotherapy in cisplatin-eligible patients.</p> <p>Key results http://www.streetinsider.com/FDA/FDA+approves+Padcev+plus+Keytruda+for+muscle-invasive+bladder+cancer/26756280.html Fri, 10 Jul 2026 11:23:17 -0400 4503 A.06822034 A.13871217 A.15882755 A.22847412 O.00000313 O.00162698 O.01115933 O.01918044 O.03960636 O.20026344 PFE http://www.streetinsider.com/FDA/FDA+approves+Padcev+plus+Keytruda+for+muscle-invasive+bladder+cancer/26756280.html <p>The U.S. Food and Drug Administration has approved Padcev (enfortumab vedotin-ejfv) combined with Keytruda (pembrolizumab) as neoadjuvant and adjuvant treatment for adult patients with muscle-invasive bladder cancer (MIBC), regardless of cisplatin eligibility, according to a statement from Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503).</p> <p>The expanded approval builds on a November 2025 FDA approval of the same combination for cisplatin-ineligible MIBC patients and is now supported by data from the Phase 3 EV-304 clinical trial, also known as KEYNOTE-B15. The trial compared neoadjuvant and adjuvant Padcev plus pembrolizumab against neoadjuvant gemcitabine and cisplatin chemotherapy in cisplatin-eligible patients.</p> <p>Key results http://www.streetinsider.com/FDA/FDA+approves+Padcev+plus+Keytruda+for+muscle-invasive+bladder+cancer/26756280.html Fri, 10 Jul 2026 11:23:17 -0400 4503 A.06822034 A.13871217 A.15882755 A.22847412 O.00000313 O.00162698 O.01115933 O.01918044 O.03960636 O.20026344 PFE http://www.streetinsider.com/FDA/FDA+approves+Padcev+plus+Keytruda+for+muscle-invasive+bladder+cancer/26756280.html <p>The U.S. Food and Drug Administration has approved Padcev (enfortumab vedotin-ejfv) combined with Keytruda (pembrolizumab) as neoadjuvant and adjuvant treatment for adult patients with muscle-invasive bladder cancer (MIBC), regardless of cisplatin eligibility, according to a statement from Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503).</p> <p>The expanded approval builds on a November 2025 FDA approval of the same combination for cisplatin-ineligible MIBC patients and is now supported by data from the Phase 3 EV-304 clinical trial, also known as KEYNOTE-B15. The trial compared neoadjuvant and adjuvant Padcev plus pembrolizumab against neoadjuvant gemcitabine and cisplatin chemotherapy in cisplatin-eligible patients.</p> <p>Key results http://www.streetinsider.com/FDA/FDA+approves+Padcev+plus+Keytruda+for+muscle-invasive+bladder+cancer/26756280.html Fri, 10 Jul 2026 11:23:17 -0400 4503 A.06822034 A.13871217 A.15882755 A.22847412 O.00000313 O.00162698 O.01115933 O.01918044 O.03960636 O.20026344 PFE http://www.streetinsider.com/FDA/FDA+approves+Padcev+plus+Keytruda+for+muscle-invasive+bladder+cancer/26756280.html <p>The U.S. Food and Drug Administration has approved Padcev (enfortumab vedotin-ejfv) combined with Keytruda (pembrolizumab) as neoadjuvant and adjuvant treatment for adult patients with muscle-invasive bladder cancer (MIBC), regardless of cisplatin eligibility, according to a statement from Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503).</p> <p>The expanded approval builds on a November 2025 FDA approval of the same combination for cisplatin-ineligible MIBC patients and is now supported by data from the Phase 3 EV-304 clinical trial, also known as KEYNOTE-B15. The trial compared neoadjuvant and adjuvant Padcev plus pembrolizumab against neoadjuvant gemcitabine and cisplatin chemotherapy in cisplatin-eligible patients.</p> <p>Key results http://www.streetinsider.com/FDA/FDA+approves+Padcev+plus+Keytruda+for+muscle-invasive+bladder+cancer/26756280.html Fri, 10 Jul 2026 11:23:17 -0400 4503 A.06822034 A.13871217 A.15882755 A.22847412 O.00000313 O.00162698 O.01115933 O.01918044 O.03960636 O.20026344 PFE http://www.streetinsider.com/FDA/FDA+approves+Padcev+plus+Keytruda+for+muscle-invasive+bladder+cancer/26756280.html <p>The U.S. Food and Drug Administration has approved Padcev (enfortumab vedotin-ejfv) combined with Keytruda (pembrolizumab) as neoadjuvant and adjuvant treatment for adult patients with muscle-invasive bladder cancer (MIBC), regardless of cisplatin eligibility, according to a statement from Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503).</p> <p>The expanded approval builds on a November 2025 FDA approval of the same combination for cisplatin-ineligible MIBC patients and is now supported by data from the Phase 3 EV-304 clinical trial, also known as KEYNOTE-B15. The trial compared neoadjuvant and adjuvant Padcev plus pembrolizumab against neoadjuvant gemcitabine and cisplatin chemotherapy in cisplatin-eligible patients.</p> <p>Key results http://www.streetinsider.com/FDA/FDA+approves+Padcev+plus+Keytruda+for+muscle-invasive+bladder+cancer/26756280.html Fri, 10 Jul 2026 11:23:17 -0400 4503 A.06822034 A.13871217 A.15882755 A.22847412 O.00000313 O.00162698 O.01115933 O.01918044 O.03960636 O.20026344 PFE http://www.streetinsider.com/FDA/FDA+approves+Padcev+plus+Keytruda+for+muscle-invasive+bladder+cancer/26756280.html <p>The U.S. Food and Drug Administration has approved Padcev (enfortumab vedotin-ejfv) combined with Keytruda (pembrolizumab) as neoadjuvant and adjuvant treatment for adult patients with muscle-invasive bladder cancer (MIBC), regardless of cisplatin eligibility, according to a statement from Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503).</p> <p>The expanded approval builds on a November 2025 FDA approval of the same combination for cisplatin-ineligible MIBC patients and is now supported by data from the Phase 3 EV-304 clinical trial, also known as KEYNOTE-B15. The trial compared neoadjuvant and adjuvant Padcev plus pembrolizumab against neoadjuvant gemcitabine and cisplatin chemotherapy in cisplatin-eligible patients.</p> <p>Key results http://www.streetinsider.com/FDA/FDA+approves+Padcev+plus+Keytruda+for+muscle-invasive+bladder+cancer/26756280.html Fri, 10 Jul 2026 11:23:17 -0400 4503 A.06822034 A.13871217 A.15882755 A.22847412 O.00000313 O.00162698 O.01115933 O.01918044 O.03960636 O.20026344 PFE http://www.streetinsider.com/FDA/FDA+approves+Padcev+plus+Keytruda+for+muscle-invasive+bladder+cancer/26756280.html <p>The U.S. Food and Drug Administration has approved Padcev (enfortumab vedotin-ejfv) combined with Keytruda (pembrolizumab) as neoadjuvant and adjuvant treatment for adult patients with muscle-invasive bladder cancer (MIBC), regardless of cisplatin eligibility, according to a statement from Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503).</p> <p>The expanded approval builds on a November 2025 FDA approval of the same combination for cisplatin-ineligible MIBC patients and is now supported by data from the Phase 3 EV-304 clinical trial, also known as KEYNOTE-B15. The trial compared neoadjuvant and adjuvant Padcev plus pembrolizumab against neoadjuvant gemcitabine and cisplatin chemotherapy in cisplatin-eligible patients.</p> <p>Key results http://www.streetinsider.com/FDA/FDA+approves+Padcev+plus+Keytruda+for+muscle-invasive+bladder+cancer/26756280.html Fri, 10 Jul 2026 11:23:17 -0400 4503 A.06822034 A.13871217 A.15882755 A.22847412 O.00000313 O.00162698 O.01115933 O.01918044 O.03960636 O.20026344 PFE http://www.streetinsider.com/FDA/FDA+approves+Padcev+plus+Keytruda+for+muscle-invasive+bladder+cancer/26756280.html <p>The U.S. Food and Drug Administration has approved Padcev (enfortumab vedotin-ejfv) combined with Keytruda (pembrolizumab) as neoadjuvant and adjuvant treatment for adult patients with muscle-invasive bladder cancer (MIBC), regardless of cisplatin eligibility, according to a statement from Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503).</p> <p>The expanded approval builds on a November 2025 FDA approval of the same combination for cisplatin-ineligible MIBC patients and is now supported by data from the Phase 3 EV-304 clinical trial, also known as KEYNOTE-B15. The trial compared neoadjuvant and adjuvant Padcev plus pembrolizumab against neoadjuvant gemcitabine and cisplatin chemotherapy in cisplatin-eligible patients.</p> <p>Key results http://www.streetinsider.com/FDA/FDA+approves+Padcev+plus+Keytruda+for+muscle-invasive+bladder+cancer/26756280.html Fri, 10 Jul 2026 11:23:17 -0400 4503 A.06822034 A.13871217 A.15882755 A.22847412 O.00000313 O.00162698 O.01115933 O.01918044 O.03960636 O.20026344 PFE http://www.streetinsider.com/FDA/FDA+approves+Padcev+plus+Keytruda+for+muscle-invasive+bladder+cancer/26756280.html <p>The U.S. Food and Drug Administration has approved Padcev (enfortumab vedotin-ejfv) combined with Keytruda (pembrolizumab) as neoadjuvant and adjuvant treatment for adult patients with muscle-invasive bladder cancer (MIBC), regardless of cisplatin eligibility, according to a statement from Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503).</p> <p>The expanded approval builds on a November 2025 FDA approval of the same combination for cisplatin-ineligible MIBC patients and is now supported by data from the Phase 3 EV-304 clinical trial, also known as KEYNOTE-B15. The trial compared neoadjuvant and adjuvant Padcev plus pembrolizumab against neoadjuvant gemcitabine and cisplatin chemotherapy in cisplatin-eligible patients.</p> <p>Key results http://www.streetinsider.com/FDA/FDA+approves+Padcev+plus+Keytruda+for+muscle-invasive+bladder+cancer/26756280.html Fri, 10 Jul 2026 11:23:17 -0400 4503 A.06822034 A.13871217 A.15882755 A.22847412 O.00000313 O.00162698 O.01115933 O.01918044 O.03960636 O.20026344 PFE http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+PADCEV%C2%AE+plus+Keytruda%C2%AE+as+Neoadjuvant+and+Adjuvant+Treatment+for+Muscle-Invasive+Bladder+Cancer+Regardless+of+Cisplatin+Eligibility/26756279.html <ul class="bwlistdisc"> <li> <i>First and only treatment regimen for adults with MIBC, regardless of cisplatin eligibility, representing a platinum-free potential standard of care </i> </li> <li> <i>Broadened approval supported by Phase 3 EV-304 data showing a nearly 50% reduction in the risk of tumor recurrence, progression or death, and a 35% reduction in the risk of death, versus standard of care in cisplatin-eligible patients  </i> </li> </ul> <p> NEW YORK &amp; TOKYO--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV® (enfortumab vedotin-ejfv), a Nectin-4 http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+PADCEV%C2%AE+plus+Keytruda%C2%AE+as+Neoadjuvant+and+Adjuvant+Treatment+for+Muscle-Invasive+Bladder+Cancer+Regardless+of+Cisplatin+Eligibility/26756279.html Fri, 10 Jul 2026 11:23:00 -0400 4503 A.06822034 A.13871217 A.15882755 A.22847412 O.00000313 O.00162698 O.01115933 O.01918044 O.03960636 O.20026344 PFE http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+PADCEV%C2%AE+plus+Keytruda%C2%AE+as+Neoadjuvant+and+Adjuvant+Treatment+for+Muscle-Invasive+Bladder+Cancer+Regardless+of+Cisplatin+Eligibility/26756279.html <ul class="bwlistdisc"> <li> <i>First and only treatment regimen for adults with MIBC, regardless of cisplatin eligibility, representing a platinum-free potential standard of care </i> </li> <li> <i>Broadened approval supported by Phase 3 EV-304 data showing a nearly 50% reduction in the risk of tumor recurrence, progression or death, and a 35% reduction in the risk of death, versus standard of care in cisplatin-eligible patients  </i> </li> </ul> <p> NEW YORK &amp; TOKYO--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV® (enfortumab vedotin-ejfv), a Nectin-4 http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+PADCEV%C2%AE+plus+Keytruda%C2%AE+as+Neoadjuvant+and+Adjuvant+Treatment+for+Muscle-Invasive+Bladder+Cancer+Regardless+of+Cisplatin+Eligibility/26756279.html Fri, 10 Jul 2026 11:23:00 -0400 4503 A.06822034 A.13871217 A.15882755 A.22847412 O.00000313 O.00162698 O.01115933 O.01918044 O.03960636 O.20026344 PFE http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+PADCEV%C2%AE+plus+Keytruda%C2%AE+as+Neoadjuvant+and+Adjuvant+Treatment+for+Muscle-Invasive+Bladder+Cancer+Regardless+of+Cisplatin+Eligibility/26756279.html <ul class="bwlistdisc"> <li> <i>First and only treatment regimen for adults with MIBC, regardless of cisplatin eligibility, representing a platinum-free potential standard of care </i> </li> <li> <i>Broadened approval supported by Phase 3 EV-304 data showing a nearly 50% reduction in the risk of tumor recurrence, progression or death, and a 35% reduction in the risk of death, versus standard of care in cisplatin-eligible patients  </i> </li> </ul> <p> NEW YORK &amp; TOKYO--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV® (enfortumab vedotin-ejfv), a Nectin-4 http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+PADCEV%C2%AE+plus+Keytruda%C2%AE+as+Neoadjuvant+and+Adjuvant+Treatment+for+Muscle-Invasive+Bladder+Cancer+Regardless+of+Cisplatin+Eligibility/26756279.html Fri, 10 Jul 2026 11:23:00 -0400 4503 A.06822034 A.13871217 A.15882755 A.22847412 O.00000313 O.00162698 O.01115933 O.01918044 O.03960636 O.20026344 PFE http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+PADCEV%C2%AE+plus+Keytruda%C2%AE+as+Neoadjuvant+and+Adjuvant+Treatment+for+Muscle-Invasive+Bladder+Cancer+Regardless+of+Cisplatin+Eligibility/26756279.html <ul class="bwlistdisc"> <li> <i>First and only treatment regimen for adults with MIBC, regardless of cisplatin eligibility, representing a platinum-free potential standard of care </i> </li> <li> <i>Broadened approval supported by Phase 3 EV-304 data showing a nearly 50% reduction in the risk of tumor recurrence, progression or death, and a 35% reduction in the risk of death, versus standard of care in cisplatin-eligible patients  </i> </li> </ul> <p> NEW YORK &amp; TOKYO--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV® (enfortumab vedotin-ejfv), a Nectin-4 http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+PADCEV%C2%AE+plus+Keytruda%C2%AE+as+Neoadjuvant+and+Adjuvant+Treatment+for+Muscle-Invasive+Bladder+Cancer+Regardless+of+Cisplatin+Eligibility/26756279.html Fri, 10 Jul 2026 11:23:00 -0400 4503 A.06822034 A.13871217 A.15882755 A.22847412 O.00000313 O.00162698 O.01115933 O.01918044 O.03960636 O.20026344 PFE http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+PADCEV%C2%AE+plus+Keytruda%C2%AE+as+Neoadjuvant+and+Adjuvant+Treatment+for+Muscle-Invasive+Bladder+Cancer+Regardless+of+Cisplatin+Eligibility/26756279.html <ul class="bwlistdisc"> <li> <i>First and only treatment regimen for adults with MIBC, regardless of cisplatin eligibility, representing a platinum-free potential standard of care </i> </li> <li> <i>Broadened approval supported by Phase 3 EV-304 data showing a nearly 50% reduction in the risk of tumor recurrence, progression or death, and a 35% reduction in the risk of death, versus standard of care in cisplatin-eligible patients  </i> </li> </ul> <p> NEW YORK &amp; TOKYO--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV® (enfortumab vedotin-ejfv), a Nectin-4 http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+PADCEV%C2%AE+plus+Keytruda%C2%AE+as+Neoadjuvant+and+Adjuvant+Treatment+for+Muscle-Invasive+Bladder+Cancer+Regardless+of+Cisplatin+Eligibility/26756279.html Fri, 10 Jul 2026 11:23:00 -0400 4503 A.06822034 A.13871217 A.15882755 A.22847412 O.00000313 O.00162698 O.01115933 O.01918044 O.03960636 O.20026344 PFE